Abstract 22P
Background
To date, empirical methods using age, type of cancer and presence of family history of cancers are used clinically to identify individuals who may benefit from genetic counselling (GC) and testing, but because these guidelines use a threshold, they provide a standard recommendation regardless of whether women have a low (e.g. 4%) or high (e.g. 40%) likelihood of being BRCA carriers. We developed the Asian Genetic Risk Calculator (ARiCa), an Asian-specific personalised genetic risk assessment tool, to determine the probability of a breast cancer patient carrying a germline BRCA1/2 pathogenic or likely pathogenic variant. The ARiCa Study was established to evaluate the impact of personalised risk score on risk perception and cancer-related distress, and uptake of GC among breast cancer patients.
Methods
The ARiCa Study is a prospective observational multicentre two-arm study where 256 incident and prevalent breast cancer patients in breast surgical clinics who have previously not received GC will be randomised to receive genetic risk assessment based on current clinical criteria (controls) or ARiCa personalised risk score. The patients’ risk perception, distress level and GC uptake were determined via researcher-administered questionnaires six weeks after risk assessment.
Results
Interim analysis of 110 patients showed that compared to controls, a greater proportion of patients receiving ARiCa scores felt that the genetic risk information provided was easy to understand (92% vs 88%, p= 0.523) and influenced their decision on GC uptake (86% vs 78%, p=0.299). More participants also proceeded with GC (47% vs 39%, p=0.526) but none of the results were statistically significant. No significant distress after receiving genetic risk assessment was reported. Patients provided with personalized scores found that the visual (96%) and numerical (90%) forms of risk presentation were more helpful than the qualitative (84%) forms.
Conclusions
These interim results showed that personalized genetic risk assessment using visual and numerical forms of risk presentation is acceptable and may be a useful tool in facilitating the uptake of GC among breast cancer patients.
Clinical trial identification
NMRR ID-21-02298-7JY (IIR).
Editorial acknowledgement
Legal entity responsible for the study
Cancer Research Malaysia.
Funding
AstraZeneca.
Disclosure
C.H. Yip: Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Invited Speaker: AstraZeneca. A.F. Abdul Aziz: Financial Interests, Personal, Invited Speaker: Roche; Non-Financial Interests, Personal, Member of Board of Directors, a non-governmental non-profit organsiations: National Cancer Society Malaysia; Non-Financial Interests, Personal, Other, Fellow: College of Surgeons, Academy of Medicine Malaysia; Non-Financial Interests, Personal, Member: Malaysian Oncological Society. W.K. Ho, B.H. Ang: Other, Institutional, Other, Pending ARiCa trademarking: Cancer Research Malaysia. S.Y. Yoon: Financial Interests, Personal, Invited Speaker, Honorarium as invited speaker: AstraZeneca. S. Teo: Financial Interests, Institutional, Research Grant, For ARiCa Study: AstraZeneca; Other, Institutional, Other, Pending ARiCa trademarking: Cancer Research Malaysia. All other authors have declared no conflicts of interest.
Resources from the same session
112P - Optimal classification and treatment strategy based on technical and oncological futures in recurrence of colorectal liver metastases
Presenter: Kosuke Kobayashi
Session: Poster Display
Resources:
Abstract
113P - Phase I/II study of capecitabine(C)/oxaliplatin(O)/irinotecan(I) combined with bevacizumab(B) in the first-line treatment of metastatic colorectal cancer (mCRC)
Presenter: Kai Ou
Session: Poster Display
Resources:
Abstract
114P - The prognostic role of LAG-3 expression in metastatic colorectal cancer
Presenter: Yi-Hsuan Huang
Session: Poster Display
Resources:
Abstract
115P - Sidedness and survival of chemo-refractory metastatic colorectal cancer treated with lonsurf or regorafenib: A nationwide population-based study in Taiwan
Presenter: Meng-Che Hsieh
Session: Poster Display
Resources:
Abstract
116P - Burden and trends of colorectal cancer in high income Asia Pacific countries from 1990-2019 and its projections of deaths to 2040: A comparative analysis
Presenter: Monika Chhayani
Session: Poster Display
Resources:
Abstract
117P - Australasian real-world treatment selection and clinical outcomes for patients with left side (LS), RAS wildtype (RASwt) metastatic colorectal cancer (mCRC)
Presenter: Vanessa Wong
Session: Poster Display
Resources:
Abstract
119P - Neoadjuvant chemoradiotherapy in the mode of hypofractionation in locally advanced rectal cancer: Is it time to change standards of care?
Presenter: Abror Abdujapparov
Session: Poster Display
Resources:
Abstract
120P - Improved clinical outcomes with cetuximab maintenance therapy in left-sided RAS/BRAF wild-type metastatic colorectal cancer: A real-world study of Hunan cancer hospital
Presenter: Xiaolin Yang
Session: Poster Display
Resources:
Abstract
121P - Single-cell sequencing reveals the role of Treg cells with high expression of BIRC3 in regulating the progression of colorectal cancer
Presenter: Yuqiu Xu
Session: Poster Display
Resources:
Abstract
122P - Distinct transcriptomic immune profiling and clinicopathological features of cribriform morphology in colorectal adenocarcinomas
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract